Chandigarh: Haryana’s Food and Drugs Administration (FDA) has suspended 966 drug sale licences and 12 manufacturing and blood centre licences over regulatory violations during a six-month enforcement drive, health minister Arti Singh Rao said on Thursday.Between April 1 and Sept 30, FDA teams inspected 13,590 drug sale units and 423 manufacturing units across the state.A total of 2,189 samples of 2,389 were tested. Eleven were found to be substandard. The department-initiated prosecution in 64 cases involving regulatory violations, while 15 cases pending in courts were disposed of. These resulted in eight convictions and seven acquittals. Another 462 cases remain pending.The drive also included 376 joint raids by police and FDA teams, leading to registration of two FIRs under the NDPS Act and four under the Medical Termination of Pregnancy (MTP) Act.In April, FDA officials seized counterfeit Mounjaro injections worth around Rs 70 lakh. In July, the Gurgaon team busted an interstate racket manufacturing and selling counterfeit Telma-AM, a hypertension drug. On July 28, the Faridabad team seized a large consignment of counterfeit propylene glycol following a complaint.Meanwhile, the department issued 2,675 retail and wholesale drug sale licences and 20 manufacturing licences. Fourteen medical institutions were granted recognition, while two manufacturing units were upgraded to WHO-GMP standards.FDA inspections expose violations at 13,590 drug outlets and 423 manufacturing units; 11 drug samples found substandard
